Three months’ clinical outcomes from a nationwide non-medical switch from originator to biosimilar infliximab in patients with inflammatory arthritis. Results from the DANBIO registry

Activity: Talks and presentationsTalks and presentations in private or public companies

Period2. Sep 2016
Event typeConference
LocationReykjavik, Iceland